Skip to main content
Addgene

pLX_EFS-Cre_ppt-del
(Plasmid #162073)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 162073 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pLX311
  • Backbone manufacturer
    Broad Institute
  • Backbone size w/o insert (bp) 8500
  • Total vector size (bp) 7398
  • Modifications to backbone
    EF1a promoter replaced with shortened EFS promoter, deletion in U3-PPT (described in Kantor et al., 2011)
  • Vector type
    Mammalian Expression, Lentiviral, Cre/Lox

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    Cre
  • Species
    Synthetic
  • Insert Size (bp)
    1032
  • Mutation
    codon-optimized for expression in M. musculus
  • Promoter EFS (part of insert)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site NsiI (not destroyed)
  • 3′ cloning site SpeI (not destroyed)
  • 5′ sequencing primer ggaattggtttaacataacaaattggctgtgg
  • 3′ sequencing primer WPRE-R (CATAGCGTAAAAGGAGCAACA);
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLX_EFS-Cre_ppt-del was a gift from Robert Manguso (Addgene plasmid # 162073 ; http://n2t.net/addgene:162073 ; RRID:Addgene_162073)
  • For your References section:

    In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Dubrot J, Lane-Reticker SK, Kessler EA, Ayer A, Mishra G, Wolfe CH, Zimmer MD, Du PP, Mahapatra A, Ockerman KM, Davis TGR, Kohnle IC, Pope HW, Allen PM, Olander KE, Iracheta-Vellve A, Doench JG, Haining WN, Yates KB, Manguso RT. Immunity. 2021 Jan 20. pii: S1074-7613(21)00001-7. doi: 10.1016/j.immuni.2021.01.001. 10.1016/j.immuni.2021.01.001 PubMed 33497609